What is Boehringer Ingelheim?
Founded in 1885, Boehringer Ingelheim is a global pharmaceutical company with a diverse portfolio spanning human pharmaceuticals, biopharmaceuticals, chemicals, and animal health products. The company's long-standing history and broad operational scope highlight its deep roots and extensive capabilities within the life sciences industry. Its focus on research and development drives innovation across its various business segments.
How much funding has Boehringer Ingelheim raised?
Boehringer Ingelheim has raised a total of $217M across 1 funding round:
Other Financing Round
$217M
Other Financing Round (2017): $217M, investors not publicly disclosed
What's next for Boehringer Ingelheim?
The recent major strategic investment signals Boehringer Ingelheim's commitment to advancing its product pipeline and expanding its market reach. This capital infusion is expected to fuel further research and development efforts, potentially leading to new therapeutic breakthroughs and enhanced animal health solutions. The company is poised for continued growth and innovation, leveraging this strategic backing to solidify its leadership in the pharmaceutical landscape.
See full Boehringer Ingelheim company page
